ETR:SAZ - STADA Arzneimit/AKT o.N. Stock Price, News & Analysis

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume92,068 shs
Average Volume51,761 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+49-6101-6030

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive SAZ News and Ratings via Email

Sign-up to receive the latest news and ratings for SAZ and its competitors with MarketBeat's FREE daily newsletter.


STADA Arzneimit/AKT o.N. (ETR:SAZ) Frequently Asked Questions

What is STADA Arzneimit/AKT o.N.'s stock symbol?

STADA Arzneimit/AKT o.N. trades on the ETR under the ticker symbol "SAZ."

Has STADA Arzneimit/AKT o.N. been receiving favorable news coverage?

Media headlines about SAZ stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. STADA Arzneimit/AKT o.N. earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for STADA Arzneimit/AKT o.N..

Who are some of STADA Arzneimit/AKT o.N.'s key competitors?

What other stocks do shareholders of STADA Arzneimit/AKT o.N. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STADA Arzneimit/AKT o.N. investors own include Prosiebensat 1 Media (PSM), Volkswagen (VOW3), Renault (RNO), VOLKSWAGEN (VLKAY), Andersons (ANDE), Celgene (CELG), Baidu (BIDU), Apogee Enterprises (APOG), Amerisafe (AMSF) and Adaptimmune Therapeutics (ADAP).

Who are STADA Arzneimit/AKT o.N.'s key executives?

STADA Arzneimit/AKT o.N.'s management team includes the folowing people:
  • Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 61)
  • Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 54)
  • Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 53)
  • Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 43)
  • Ms. Kay Reubelt, Director of Investor Relations

What is STADA Arzneimit/AKT o.N.'s official website?

The official website for STADA Arzneimit/AKT o.N. is http://www.stada.de/.

How can I contact STADA Arzneimit/AKT o.N.?

STADA Arzneimit/AKT o.N.'s mailing address is Stadastrasse 2-18, BAD VILBEL, 61118, Germany. The company can be reached via phone at +49-6101-6030.


MarketBeat Community Rating for STADA Arzneimit/AKT o.N. (ETR SAZ)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about STADA Arzneimit/AKT o.N. and other stocks. Vote "Outperform" if you believe SAZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Featured Article: Trade War

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel